For the Treatment of Second-Line Platinum Sensitive Advanced Ovarian Cancer, One-Third of Surveyed Oncologists Indicate That Paclitaxel/Carboplatin Has the Best Overall Clinical Profile When Compared to Other Currently Available Therapies | Business Wire
Links shared publicly online about this topic.
- 549total visits
For the Treatment of Second-Line Platinum Sensitive Advanced Ovarian Cancer, One-Third of Surveyed Oncologists Indicate That Paclitaxel/Carboplatin Has the Best Overall Clinical Profile When Compared to Other Currently Available Therapies | Business Wire
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatme
View full resource at businesswire.com
Tags: Cancer, Ovarian Cancer, Pharma, Women's Health, Oncologist, Oncology
Most Recently Shared on January 27, 2011 at 8:25 pm By:
For the Treatment of Second-Line Platinum Sensitive Advanced Ovarian Cancer, One-Third of Surveyed Oncologists .... http://bit.ly/gehjWc
Advertisement
